Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line

Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line

Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell prolifera...

Full description

Bibliographic Details
Main Authors: Hisham Saafan, Ahmad Alahdab, Robin Michelet, Linus Gohlke, Janine Ziemann, Stefan Holdenrieder, Katie-May McLaughlin, Mark N. Wass, Jindrich Cinatl, Martin Michaelis, Charlotte Kloft, Christoph A Ritter
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cells
Subjects:
non-small cell lung cancer
epidermal growth factor receptor
drug resistance
cell proliferation regulating inhibitor of protein phosphatase 2A
bortezomib
Online Access:https://www.mdpi.com/2073-4409/10/4/716

Internet

https://www.mdpi.com/2073-4409/10/4/716

Similar Items